HomeAgendaMarketplace
Register
Register
Register

Ramin Masoumi

CEO

IVRS

Lund, Sweden

10 profile visits

Prof. at Lund Univ. Sweden and founder of the company IVRS, focusing on oncology and preclinical imaging.

My organisation

IVRS

IVRS

SME - Small and medium-sized enterprises

Lund, Sweden

IVRS: Pioneering Preclinical CRO for Accelerating Drug Discovery IVRS is a cutting-edge preclinical contract research organization (CRO) focused on advancing drug discovery and validation for severe human diseases with critical unmet medical needs. Our comprehensive expertise in both in vitro and in vivo models spans cancer, neurodegenerative diseases, and inflammatory disorders, positioning us to fast-track the development of life-changing therapies. We specialize in monitoring disease progression and treatment efficacy over time in living animal models through advanced imaging technologies. Our deep-tissue and whole-body 3D imaging capabilities provide real-time insights, allowing for the precise tracking of individual variations. This enables the design of safer, more effective therapies, ultimately bringing innovative solutions to clinical studies.
Read more

About me

Dr. Ramin Massoumi is a Professor and Principal Investigator at Lund University, Sweden. After earning a PhD from Lund University and completing postdoctoral training at the Max Planck Inst. for Biochemistry in Germany, Dr. Massoumi now leads a research group focused on cancer biology and the development of novel anticancer drugs. As the founder of the Company IVRS, Dr. Massoumi contributes to cancer research both academically and commercially.

My organisation

IVRS: Pioneering Preclinical CRO for Accelerating Drug Discovery

IVRS is a cutting-edge preclinical contract research organization (CRO) focused on advancing drug discovery and validation for severe human diseases with critical unmet medical needs.

Our comprehensive expertise in both in vitro and in vivo models spans cancer, neurodegenerative diseases, and inflammatory disorders, positioning us to fast-track the development of life-changing therapies.

We specialize in monitoring disease progression and treatment efficacy over time in living animal models through advanced imaging technologies. Our deep-tissue and whole-body 3D imaging capabilities provide real-time insights, allowing for the precise tracking of individual variations. This enables the design of safer, more effective therapies, ultimately bringing innovative solutions to clinical studies.

Social media

Marketplace (4)